Clinical Trials Directory

Trials / Completed

CompletedNCT04995289

Prone Position During ECMO in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Hypoxaemic Patient

Prone Position During ECMO in Covid Hypoxaemic Patient :A PROCESS-compliant Case Series From the Eastern Morocco

Status
Completed
Phase
Study type
Observational
Enrollment
23 (actual)
Sponsor
Mohammed VI University Hospital · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

Introduction: The main manifestation of COVID-19 pneumonia is acute respiratory distress syndrome (ARDS), which in some cases can be more severe than intubation, extracorporeal membrane venous oxygenation (VV-ECMO) to ensure hematosis. Despite support from VV-ECMO, some patients may remain hypoxemic. One possible therapeutic procedure for these patients is the application of the prone position. Objective: The main aim of this study was to investigate the modification of the PaO2/FiO2 ratio, the compliance of the respiratory system in VV-ECMO with refractory hypoxemia. The secondary objective was to evaluate the safety and feasibility of the inclined position for ECMO. Methods: the investigators reviewed the electronic records and lists of all 23 COVID-19 patients. were placed for the first time in PP with an average duration of 16 h . patient characteristics, pre-ECMO characteristics, ventilator/ECMO settings, and changes in ventilator/ECMO settings and blood gas analysis before and after PP.

Detailed description

The main objective of the current study was to investigate the change in PaO2/FiO2 ratio, the compliance of the respiratory system in VV-ECMO patients with persistent hypoxemia. Measurements were taken before PP, 1 h after the start of the PP, at the end of the PP cycle. The secondary objective of this study was to assess the safety and feasibility of emergency positioning for patients with severe ARDS during ECMO treatment.

Conditions

Interventions

TypeNameDescription
OTHERProne position on ECMO patientblood gas analysis before and after PP

Timeline

Start date
2020-01-01
Primary completion
2021-01-30
Completion
2021-01-30
First posted
2021-08-06
Last updated
2021-08-13

Locations

1 site across 1 country: Morocco

Source: ClinicalTrials.gov record NCT04995289. Inclusion in this directory is not an endorsement.